Allogene Therapeutics (ALLO) Stock Forecast & Price Target

Compare

1,440 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ALLO Analyst Ratings

Strong Buy

11 Buy

2 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Allogene

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ALLO Stock 12 Month Forecast

Average Price Target

$8.15

▲(526.92%Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Allogene Therapeutics in the last 3 months. The average price target is $8.15 with a high forecast of $14.00 and a low forecast of $2.50. The average price target represents a 526.92% change from the last price of $1.30.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","15":"$15","3.75":"$3.75","7.5":"$7.5","11.25":"$11.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.15</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.75,7.5,11.25,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.27,2.249230769230769,3.2284615384615387,4.207692307692308,5.186923076923077,6.166153846153847,7.145384615384616,8.124615384615385,9.103846153846154,10.083076923076923,11.062307692307693,12.041538461538462,13.02076923076923,{"y":14,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.27,1.7992307692307694,2.3284615384615384,2.8576923076923078,3.386923076923077,3.9161538461538465,4.445384615384615,4.974615384615385,5.503846153846155,6.033076923076923,6.562307692307693,7.0915384615384625,7.6207692307692305,{"y":8.15,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.27,1.3646153846153846,1.4592307692307693,1.5538461538461539,1.6484615384615384,1.7430769230769232,1.8376923076923077,1.9323076923076923,2.026923076923077,2.121538461538462,2.216153846153846,2.310769230769231,2.4053846153846155,{"y":2.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.92,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.5,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.33,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.74,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.67,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.72,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.55,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.13,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.8,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.95,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.37,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.69,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.27,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$14.00

Average Price Target$8.15

Lowest Price Target$2.50

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$1.5

Hold

15.38%

Upside

Reiterated

06/07/25

The overall stock score is primarily influenced by significant financial challenges, including declining revenues and persistent losses. Technical indicators also suggest a bearish trend. While the earnings call provided some optimism with clinical trial advancements, operational delays and financial losses remain substantial hurdles.

William PickeringBernstein

Bernstein

$3→$2.5

Hold

92.31%

Upside

Reiterated

06/05/25

Allogene Therapeutics (ALLO) Receives a Hold from Bernstein

Biren AminPiper Sandler

Piper Sandler

Buy

438.46%

Upside

Reiterated

06/02/25

Allogene Therapeutics (ALLO) Receives a Buy from Piper Sandler

Tyler Van BurenTD Cowen

TD Cowen

―

Buy

―

Reiterated

06/02/25

Allogene Therapeutics (ALLO) Receives a Buy from TD Cowen

John NewmanCanaccord Genuity

Canaccord Genuity

$14

Buy

976.92%

Upside

Reiterated

06/02/25

Canaccord Genuity Reaffirms Their Buy Rating on Allogene Therapeutics (ALLO)

Samantha SemenkowCiti

Citi

Buy

207.69%

Upside

Reiterated

06/02/25

Citi Keeps Their Buy Rating on Allogene Therapeutics (ALLO)

Robert BurnsH.C. Wainwright

H.C. Wainwright

Buy

515.38%

Upside

Reiterated

06/02/25

Promising Clinical Results and Strategic Initiatives Drive Buy Rating for Allogene Therapeutics

Sami CorwinWilliam Blair

William Blair

―

Buy

―

Reiterated

05/14/25

Positive Outlook on Allogene Therapeutics Amid ALPHA3 Trial Delays and Market Expansion Potential

Matthew BieglerOppenheimer

Oppenheimer

$10→$9

Buy

592.31%

Upside

Reiterated

05/14/25

Analysts Are Bullish on Top Healthcare Stocks: Allogene Therapeutics (ALLO), Biodesix (BDSX)

Asthika GoonewardeneTruist Financial

Truist Financial

$14→$10

Buy

669.23%

Upside

Reiterated

05/14/25

Reni BenjaminCitizens JMP

Citizens JMP

―

Hold

―

Downgraded

05/14/25

Allogene downgraded to Market Perform from Outperform at Citizens JMPAllogene downgraded to Market Perform from Outperform at Citizens JMP

Jack AllenRobert W. Baird

Robert W. Baird

$12→$9

Buy

592.31%

Upside

Reiterated

05/14/25

Allogene Therapeutics price target lowered to $9 from $12 at BairdAllogene Therapeutics price target lowered to $9 from $12 at Baird

Michael YeeJefferies

Jefferies

Buy

515.38%

Upside

Reiterated

05/13/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: GlaxoSmithKline (LSE: GB:GSK), Sartorius Stedim Biotech (LSE: GB:0RG8) and Allogene Therapeutics (NASDAQ: ALLO)

Luca IssiRBC Capital

RBC Capital

$10

Buy

669.23%

Upside

Reiterated

05/13/25

Allogene Therapeutics (ALLO) Gets a Buy from RBC Capital

Benjamin BurnettStifel Nicolaus

Stifel Nicolaus

Hold

207.69%

Upside

Reiterated

03/17/25

Stifel Nicolaus Keeps Their Hold Rating on Allogene Therapeutics (ALLO)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$1.5

Hold

15.38%

Upside

Reiterated

06/07/25

William PickeringBernstein

Bernstein

$3→$2.5

Hold

92.31%

Upside

Reiterated

06/05/25

Allogene Therapeutics (ALLO) Receives a Hold from Bernstein

Biren AminPiper Sandler

Piper Sandler

Buy

438.46%

Upside

Reiterated

06/02/25

Allogene Therapeutics (ALLO) Receives a Buy from Piper Sandler

Tyler Van BurenTD Cowen

TD Cowen

―

Buy

―

Reiterated

06/02/25

Allogene Therapeutics (ALLO) Receives a Buy from TD Cowen

John NewmanCanaccord Genuity

Canaccord Genuity

$14

Buy

976.92%

Upside

Reiterated

06/02/25

Canaccord Genuity Reaffirms Their Buy Rating on Allogene Therapeutics (ALLO)

Samantha SemenkowCiti

Citi

Buy

207.69%

Upside

Reiterated

06/02/25

Citi Keeps Their Buy Rating on Allogene Therapeutics (ALLO)

Robert BurnsH.C. Wainwright

H.C. Wainwright

Buy

515.38%

Upside

Reiterated

06/02/25

Promising Clinical Results and Strategic Initiatives Drive Buy Rating for Allogene Therapeutics

Sami CorwinWilliam Blair

William Blair

―

Buy

―

Reiterated

05/14/25

Positive Outlook on Allogene Therapeutics Amid ALPHA3 Trial Delays and Market Expansion Potential

Matthew BieglerOppenheimer

Oppenheimer

$10→$9

Buy

592.31%

Upside

Reiterated

05/14/25

Analysts Are Bullish on Top Healthcare Stocks: Allogene Therapeutics (ALLO), Biodesix (BDSX)

Asthika GoonewardeneTruist Financial

Truist Financial

$14→$10

Buy

669.23%

Upside

Reiterated

05/14/25

Reni BenjaminCitizens JMP

Citizens JMP

―

Hold

―

Downgraded

05/14/25

Allogene downgraded to Market Perform from Outperform at Citizens JMPAllogene downgraded to Market Perform from Outperform at Citizens JMP

Jack AllenRobert W. Baird

Robert W. Baird

$12→$9

Buy

592.31%

Upside

Reiterated

05/14/25

Allogene Therapeutics price target lowered to $9 from $12 at BairdAllogene Therapeutics price target lowered to $9 from $12 at Baird

Michael YeeJefferies

Jefferies

Buy

515.38%

Upside

Reiterated

05/13/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: GlaxoSmithKline (LSE: GB:GSK), Sartorius Stedim Biotech (LSE: GB:0RG8) and Allogene Therapeutics (NASDAQ: ALLO)

Luca IssiRBC Capital

RBC Capital

$10

Buy

669.23%

Upside

Reiterated

05/13/25

Allogene Therapeutics (ALLO) Gets a Buy from RBC Capital

Benjamin BurnettStifel Nicolaus

Stifel Nicolaus

Hold

207.69%

Upside

Reiterated

03/17/25

Stifel Nicolaus Keeps Their Hold Rating on Allogene Therapeutics (ALLO)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Allogene Therapeutics

1 Month

xxx

Success Rate

6/15 ratings generated profit

Average Return

-4.79%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 40.00% of your transactions generating a profit, with an average return of -4.79% per trade.

3 Months

xxx

Success Rate

8/16 ratings generated profit

Average Return

-3.43%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of -3.43% per trade.

1 Year

John NewmanCanaccord Genuity

Success Rate

6/23 ratings generated profit

Average Return

-25.26%

reiterated a buy rating 17 days ago

Copying John Newman's trades and holding each position for 1 Year would result in 26.09% of your transactions generating a profit, with an average return of -25.26% per trade.

2 Years

xxx

Success Rate

3/14 ratings generated profit

Average Return

-42.91%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 21.43% of your transactions generating a profit, with an average return of -42.91% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ALLO Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ALLO has received 19 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. ALLO average Analyst price target in the past 3 months is 8.15.

Each month's total comprises the sum of three months' worth of ratings.

ALLO Financial Forecast

ALLO Earnings Forecast

Next quarter’s earnings estimate for ALLO is -$0.27 with a range of -$0.30 to -$0.21. The previous quarter’s EPS was -$0.28. ALLO beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year ALLO has Outperformed its overall industry.

ALLO Sales Forecast

Next quarter’s sales forecast for ALLO is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. ALLO beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year ALLO has Preformed in-line its overall industry.

ALLO Stock Forecast FAQ

What is ALLO’s average 12-month price target, according to analysts?

Based on analyst ratings, Allogene Therapeutics Inc’s 12-month average price target is 8.15.

What is ALLO’s upside potential, based on the analysts’ average price target?

Allogene Therapeutics Inc has 526.92% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ALLO a Buy, Sell or Hold?

Allogene Therapeutics Inc has a consensus rating of Strong Buy which is based on 11 buy ratings, 2 hold ratings and 0 sell ratings.

What is Allogene Therapeutics Inc’s price target?

The average price target for Allogene Therapeutics Inc is 8.15. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $14.00 ,the lowest forecast is $2.50. The average price target represents 526.92% Increase from the current price of $1.3.

What do analysts say about Allogene Therapeutics Inc?

Allogene Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of ALLO?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Allogene Therapeutics (ALLO) Stock Forecast & Price Target

ALLO Analyst Ratings

ALLO Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Allogene Therapeutics

ALLO Analyst Recommendation Trends

ALLO Financial Forecast

ALLO Earnings Forecast

ALLO Sales Forecast

ALLO Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts